Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 2Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Head & Neck 1

Conditions

Leukemia, Myeloid, Acute 55Precursor Cell Lymphoblastic Leukemia-Lymphoma 45Myelodysplastic Syndromes 42Leukemia, Lymphocytic, Chronic, B-Cell 40Leukemia 38Lymphoma, Non-Hodgkin 32Multiple Myeloma 31Lymphoma 31Lymphoma, Mantle-Cell 26Lymphoma, Follicular 24Lymphoma, Large B-Cell, Diffuse 23Hodgkin Disease 22Melanoma 21Burkitt Lymphoma 19Lymphoma, B-Cell, Marginal Zone 18Leukemia, Myelomonocytic, Chronic 17Recurrence 14Anemia, Refractory, with Excess of Blasts 14Congenital Abnormalities 13Neoplasms, Plasma Cell 12Myeloproliferative Disorders 12Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Large-Cell, Immunoblastic 11Hematologic Neoplasms 11Leukemia, Myeloid, Chronic-Phase 10Primary Myelofibrosis 9Lymphoma, Large-Cell, Anaplastic 9Lymphoma, B-Cell 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Ovarian Neoplasms 8

Interventions

Gemcitabine 6pembrolizumab 5toripalimab 2fludarabine 2Valproic Acid 2Valganciclovir 2Injections 2Cyclophosphamide 2Cisplatin 2130-nm albumin-bound paclitaxel 2tislelizumab 1spartalizumab 1sapropterin 1fosaprepitant 1fludarabine phosphate 1camrelizumab 1Surgical Procedures, Operative 1Specimen Handling 1SHR-1701 1Protons 1Proton Therapy 1Panobinostat 1Medicare Part B 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Interleukin-2 1Floxuridine 1Everolimus 1Dexamethasone 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Nasopharyngeal Carcinoma × fludarabine phosphate × Clear all
NCT02287311 2026-03-23

MABEL

Baylor College of Medicine

Phase 1 Active not recruiting
38 enrolled 16 charts
Head & NeckLymphoid

Nasopharyngeal Carcinoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, Smooth Muscle Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡